I think the market reaction is a reflection that the in-vivo testing was mostly (not 100%) good on a very small number of animals, and the Mousey equivalent of human Phase 3 testing might be needed.
So, to help the farming industry, quite a sizable volunteer chicken flock might well be required now.
It's curious that, in the NR, the Snis comments upon the encouraging results with the mice, but then Doc Miller makes a comment about seasonal flu suffered by 'people.'
Why was that included ?
Presumably to nudge the market along the pathway that says "It's a few mice today, but one day it will be Phase 3 testing on about 2000 humans.
We are quite a long way away from Phase1 aptamer bird-flu vaccine trials on human recipients.
What you won't find Doc Miller telling us, and the market, is how long it takes to complete human trials at Phases 1/2/3.
Even if such trials are successful at each mile-marker we would be looking at end 2029/early 2030 before mass production and mass prophylactic treatment would be ready if a pandemic broke out.
The NR was very encouraging as a 'so far, pretty good' indicator, but was slightly disingenuous about human bird flu vaccines. |
